Profile
AYTU ZTS TAK HLN TEVA NBIX
Company Name Aytu BioPharma, Inc. Zoetis Inc. Takeda Pharmaceutical Company Limited Haleon plc Teva Pharmaceutical Industries Limited Neurocrine Biosciences, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $14.56M $67.90B $47.69B $43.90B $22.86B $14.30B
Employees 0.10K 13.80K 49.28K 24.56K 37.00K 1.80K
CEO Joshua R. Disbrow Kristin C. Peck Christophe Weber Brian James McNamara Richard D. Francis Kyle W. Gano
Ratings
AYTU ZTS TAK HLN TEVA NBIX
Quant Rating Score 3 3 3 3 1 4
Quant Rating Neutral Neutral Neutral Neutral Strong Sell Buy
Trading
AYTU ZTS TAK HLN TEVA NBIX
Last Close $2.36 $148.2 $15.1 $9.81 $19.93 $141.87
High 52 $2.85 $196.48 $15.52 $11.41 $22.77 $153.29
Low 52 $1 $144.45 $12.89 $9.01 $12.82 $87.59
Price vs. 52 Week High -17.19 % -24.57 % -2.71 % -14.02 % -12.47 % -7.45 %
Price vs. 52 Week Low 136 % 2.6 % 17.15 % 8.88 % 55.46 % 61.97 %
Total Return
AYTU ZTS TAK HLN TEVA NBIX
1 Month Return 6.79 % -3.83 % 0.67 % 1.66 % 11.59 % 6.75 %
3 Month Return 21.03 % -9.82 % -0.66 % -9.75 % 17.3 % 14.05 %
6 Month Return 95.87 % -8.1 % 0.6 % -3.35 % 22.05 % 28.1 %
9 Month Return 63.89 % -16.83 % 12.52 % 0.51 % 20.79 % 11.97 %
YTD Return 38.82 % -9.04 % 14.05 % 2.83 % -9.57 % 3.93 %
1 Year Return -8.53 % -22.44 % 2.72 % -6.66 % 8.26 % 16.05 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
AYTU ZTS TAK HLN TEVA NBIX
Dividend Yield Percentage (TTM) - 1.26 % 4.36 % 0.02 % - -
Dividend Paid and Capex Coverage Ration (TTM) -26.2 % 1.89 % 2.03 % - 2.78 % 14.7 %
Dividend Per Share (TTM) - 1.93 % 196 % 0.06 % - -
Payout Ratio (TTM) - 32.08 % 226.17 % - - -
Growth
AYTU ZTS TAK HLN TEVA NBIX
Asset Growth -13.46 % -5.7 % -9.55 %
Gross Profit Growth -25.9 % 5.97 % 5.47 %
Revenue Growth -24.58 % 7.45 % 4.4 %
Revenue 3 Year -81.28 % 25.02 % 1.52 %
Revenue 5 Year -92.21 % 35.03 % -5.5 %
Revenue 10 Year -99.78 % 151.79 % -38.45 %
EBIT Growth 23.2 % 160.62 % -167.63 %
Net Income Growth 7.08 % -25.08 % -193.2 %
Net Income 3 Yeari Growth Per Share 95.88 % -54.31 % -482.97 %
Net Income 5 Yeari Growth Per Share 99.76 % 136.64 % -58.26 %
Net Income 10 Yeari Growth Per Share 100 % 172.34 % -140.46 %
Operating Income Growth 69.21 % 60.03 % -169.98 %
Operating Cash Flow Growth (CFG) 72.94 % 47.58 % -8.85 %
Operating 3 Year CFG 99.19 % -8.32 % 52.26 %
Operating 5 Year CFG 99.93 % 53.11 % 123.59 %
Operating 10 Year CFG 100 % 465.93 % -81.66 %
EPS Growth 44.03 % -25.78 % -190 %
EPS Diluted Growth 44.03 % -26.25 % -190 %
Book Value Per Share -57.53 % -7.08 % -30.36 %
Share Holder 3 Year Equity Growth Per Share -96.94 % 18.85 % -49 %
Share Holder 5 Year Equity Growth Per Share -97.25 % 42.42 % -62.86 %
Share Holder 10 Year Equity Growth Per Share -100 % 217.07 % -82.6 %
Dividend Per Share Growth - 2.65 % -
Dividend 3 Year Growth Per Share - 3.86 % -
Dividend 5 Year Growth Per Share - 3.84 % -100 %
Dividend 10 Year Growth Per Share - 108.67 % -100 %
Debt Growth -11.02 % 4.59 % -10.29 %
Free Cash Flow Growth 72.94 % 263.47 % -11.05 %
Updated On 30 Jun 2024 31 Mar 2025 31 Dec 2024
Profitability
AYTU ZTS TAK HLN TEVA NBIX
Gross Profit Margin TTM 68.59 % 70.03 % 60.54 % 61.52 % 49.6 % 98.49 %
Return on Assets TTM 1.32 % 18.04 % 0.98 % 4.2 % -0.39 % 8.95 %
Return on Equity TTM 5.32 % 53.21 % 1.95 % 8.74 % -2.58 % 13.22 %
Return on Capital Employed TTM -7.2 % 31.67 % 3.43 % 7.74 % 3.16 % 14.8 %
Net Income Per EBT TTM 92.29 % 78.72 % 72.1 % 75.5 % 222.54 % 66.08 %
EBT Per Ebit TTM -46.08 % 94.26 % 46.84 % 86.58 % -7.94 % 106.48 %
EBIT Per Revenue TTM -5.57 % 37.51 % 9.05 % 19.64 % 5.38 % 19.72 %
Cash Flow To Debt Ratio TTM -25.81 % 43.13 % 23.79 % - 7.93 % 129.2 %
Receivables Turnover TTM 1.93 6.09 6.59 5.9 4.67 4.21
Payables Turnover TTM 1.81 5.54 4.53 2.19 3.35 0.36
Inventory Turnover TTM 1.97 1.15 1.54 3.63 2.4 0.66
Fixed Asset Turnover TTM 4177.61 % 244.46 % 229.02 % 584.75 % 321.73 % 429.78 %
Asset Turnover TTM 55.73 % 64.82 % 31.99 % 32.73 % 41.43 % 64.53 %
Operating Cash Flow Per Share TTM -0.9 6.58 684.97 - 1.21 5.73
Free Cash Flow Per Share TTM -0.94 4.99 531.34 - 0.78 5.34
Cash Per Share TTM 296.24 % 322.4 % 26788.97 % 24.05 % 188.4 % 985.45 %
Operating Cash Flow Sales Ratio TTM -7.99 % 31.21 % 23.92 % - 8.36 % 22.6 %
Free Cash Flow Operating Cash Flow Ratio TTM 103.82 % 75.76 % 77.57 % - 64.03 % 93.2 %
Cash Flow Coverage Ratios TTM -25.81 % 43.13 % 23.79 % - 7.93 % 129.2 %
Price To Free Cash Flows Ratio TTM -2.54 30.6 8.44 - 25.45 27.05
Price To Operating Cash Flows Ratio TTM -2.62 23.28 6.56 - 16.3 25.16
Price Cash Flow Ratio TTM -2.62 23.28 6.56 - 16.3 25.16
Income Statement (TTM)
AYTU ZTS TAK HLN TEVA NBIX
Revenue $0.08B $9.26B $4581.55B $11.23B $16.54B $2.36B
Gross Profit $0.05B $6.4B $3001.33B $6.95B $8.06B $2.32B
Gross Profit Ratio 60.95% 69.1% 65.51% 61.85% 48.74% 98.56%
EBITDA $-0B $3.87B $1210.51B $2.51B $0.78B $0.64B
Net Income $-0.02B $2.49B $107.93B $1.44B $-1.64B $0.34B
EPS Diluted -2.86 5.47 33.62 0.32 -1.45 3.29
Balance Sheet (MRQ)
AYTU ZTS TAK HLN TEVA NBIX
Long Term Debt $0.01B $5.39B $4517.23B $8.54B $16.3B $0.46B
Total Liabilities $0.09B $9.47B $7312.37B $18.09B $33.61B $1.13B
Total Equity $0.03B $4.77B $6935.98B $16.22B $5.72B $2.59B
Total Investments $-0B $0B $10.8B $0.08B $0B $1.71B
Total Debt $0.02B $6.74B $5066.17B $10.1B $18.08B $0.46B
Total Assets $0.12B $14.24B $14248.34B $34.32B $39.33B $3.72B
Cash Flow Statement (TTM)
AYTU ZTS TAK HLN TEVA NBIX
Net Income $-0.02B $2.5B $107.93B $1.44B $-1.96B $0.34B
Inventory $0B $-0.04B $-34.97B $0.22B $0.17B $-0.02B
Dividends Paid $0B $-0.79B $-302.5B $-0.57B $0B $0B
Operating Cash Flow $-0B $2.95B $1057.18B $2.3B $1.25B $0.6B
Capital Expenditure $0B $-0.66B $-200.8B $-0.25B $-0.5B $-0.04B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 4.97
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
AKAN Akanda Corp. 3.35
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 8.12
ALVOW Alvotech 1.13
AMPH Amphastar Pharmaceuticals, Inc. 27.265
AMRX Amneal Pharmaceuticals, Inc. 9.795
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 98.84
APUS Apimeds Pharmaceuticals US, Inc 2.03
AQST Aquestive Therapeutics, Inc. 5.135
ASRT Assertio Holdings, Inc. 0.8098
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 15.185
ETFs With Exposure to AYTU
Ticker ETF Name Weight Percentage Price
ITOT iShares Core S&P Total U.S. Stock Market ETF 0.00001 144.68
VXF Vanguard Extended Market Index Fund 0.00019 209.37
PQSV PGIM ETF Trust - PGIM QMA Strategic Alpha Small-Cap Value ETF 0.1 66.2468
DFAT Dimensional U.S. Targeted Value ETF 0.00000354 58.79
DFAS Dimensional U.S. Small Cap ETF 0.00008852 68.56
DFAC Dimensional U.S. Core Equity 2 ETF 0.0000058 38.37
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0.00019 158.47
DFSU Dimensional US Sustainability Core 1 ETF 0.00065586 42.195
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0.00019 158.48
JKK iShares Morningstar Small-Cap Growth ETF 0 307.42
JKL iShares Morningstar Small-Cap Value ETF 0 172.726
VEMPX Vanguard Extended Market Index InstlPlus 0.00019 391.07
Unlock